Drug Discovery World

JULY 30, 2024

Tecvayli (teclistamab) has been recommended for relapsed and refractory multiple myeloma (RRMM) in England and Wales, leading analysts to predict Johnson & Johnson (J&J) will dominate the bispecific T-cell engagers (BiTEs) market by 2030. By 2030, GlobalData predicts BiTEs to generate $20.6 billion in global sales.

Marketing 130

Marketing Treatment Therapies Production 130

Drug Discovery World

MAY 28, 2024

billion by 2030, growing at a CAGR of 15.3% from 2023 to 2030. Download this exclusive eBook to learn more about: How new imaging modalities are supporting the development of new therapies for cancer and neurodegenerative diseases. billion in 2023 and is poised to reach $15.58

Drugs 130

Drugs Clinical Trials Marketing Disease 130

Drug Discovery World

MARCH 2, 2023

With our pre|CISION and Affimer platforms we have an unparalleled opportunity to develop really meaningful new cancer therapies, by developing targeted therapies, multi-specific immunotherapies, difficult to drug targets, and next-generation cell therapies.”

Therapies 130

Therapies Treatment Trials Disease 130

Drug Discovery World

JANUARY 18, 2024

Market opportunity estimated at over US$1 billion Largely due to the CRS risk (which can be life threatening), administration of cancer immunotherapies, such as bispecific antibodies, is currently restricted to specialist cancer centres which limits uptake of these therapies. million cases of cancer by 2030 1,2.

Treatment 163

Treatment Clinical Trials Immune Response Therapies 163

Drug Discovery World

JULY 11, 2022

David Lewandowski, Business Director of Cell & Gene Therapy at Azenta Life Sciences, explains how efficient sample management can help to work efficiently and bring therapies to market faster. The global cell and gene therapy (CGT) market reached a value of ~$4 billion in 2020 and is expected to grow to ~$34 billion by 2030 1.

Therapies 130

Therapies Clinical Trials Production Trials 130

Drug Discovery World

AUGUST 2, 2024

GLP-1 receptor agonist slows Alzheimer’s cognitive decline In new revelations about glucagon-like peptide-1 (GLP-1) drugs like Ozempic, a study has demonstrated the therapies could protect against dementia. relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalisation after 12 weeks of treatment.

Clinical Trials 130

Clinical Trials Drugs Treatment Disease 130

Drug Discovery World

APRIL 8, 2024

The 2023 report evaluates the company’s progress across its strategic Environmental, Social and Governance (ESG) areas of focus: Accelerate Life-Saving Therapies; Lead with Integrity; Inspire our People; and Protect our Planet. The work we do at Charles River today extends beyond science. million in projects by the end of 2023.

FDA 130

FDA Laboratories Government Science 130

Drug Discovery World

MAY 6, 2024

A more established Amsterdam-based enterprise is gene therapy company uniQure, developer of etranacogene dezaparvovec, the first gene therapy for haemophilia B, which was approved for use in the US in November 2022 and in the EU in February 2023. The rights for etranacogene dezaparvovec were subsequently sold to CSL Pharmaceuticals.

Drugs 148

Drugs Science Molecular Biology Clinical Trials 148

thought leadership

JUNE 4, 2024

The HTAR will take effect in January 2025 for oncology and/or advanced therapy medicinal product (ATMP) therapies, with other therapies following a staggered implementation process, including orphan drugs in 2028 and all drugs in 2030.

Therapies 59

Therapies Regulations Production Marketing 59

Drug Discovery World

DECEMBER 7, 2023

The group examined barriers to translating basic science into effective therapies for MND and suggested guiding principles for future research. MND drug repurposing fund The fund is part of LifeArc’s multi-million pound Motor Neuron Disease Translational Challenge to make MND treatable by 2030 and ultimately find a cure.

Bioinformatics 130

Bioinformatics Clinical Trials Drugs Trials 130

Drug Discovery World

DECEMBER 12, 2023

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study. During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity.

Small Molecule 130

Small Molecule Trials Pharmacokinetics Treatment 130

Drug Discovery World

MAY 31, 2024

billion by 2030, according to a market research report by Market Research Future. Neuropsychopharmacology profile analysis shows the drug demonstrates antipsychotic activity and has a mechanism of action distinct from FDA-approved therapies for schizophrenia and other mental conditions that present psychotic symptoms.

Licensing 148

Licensing Licensing FDA Approval Drugs 148

Drug Discovery World

NOVEMBER 7, 2023

BASE director, Associate Professor Tim Mercer said the project will cement the facility’s footing in the growing mRNA industry, which was worth $55 billion in 2022 and tipped to grow to $107 billion globally by 2030. “We aim to begin manufacturing mRNA for Phase I clinical trials in 2024.”

Clinical Trials 130

Clinical Trials Government Vaccine Laboratories 130

Drug Discovery World

AUGUST 14, 2023

Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at AmerisourceBergen, and Cori Gorman, Senior Director of CMC and Regulatory Affairs at Biopharma Excellence, offer advice on navigating the different and sometimes contradictory regulatory requirements in the US and EU. billion in 2020 to $15.5 billion 1.

Marketing 130

Marketing DNA Therapies FDA 130

Drug Discovery World

MAY 22, 2023

By investing in collaborative projects LifeArc will deliver new tests, therapies and other medical technologies with the ultimate goal of making MND treatable by 2030. Its strategy will concentrate on fast tracking scientific discoveries into new clinical solutions that will transform the way MND is detected, treated and managed.

Disease 130

Disease Clinical Trials Laboratories Treatment 130

The Pharma Data

OCTOBER 14, 2021

Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. This designation for gantenerumab marks the 39th Breakthrough Therapy Designation for Roche’s portfolio of medicines. trillion per year by 2030.

Disease 52

Disease Therapies FDA Trials 52

Drug Discovery World

JULY 31, 2023

DDW’s Reece Armstrong speaks to Hendrik Streefkerk , Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases.

Clinical Trials 130

Clinical Trials Hospitals Therapies Trials 130

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). In the US alone, there was an increase of 8 million new caregivers from 2015 to 2020 3.

Therapies 40

Therapies Disease Treatment FDA Approval 40

The Pharma Data

MARCH 23, 2023

The new state-of-the-art facility will be the largest of its kind in the country and is expected to be operational by around 2030. Takeda has delivered plasma therapies to meet the needs of patients in Japan for more than 70 years. This represents Takeda’s largest ever investment in manufacturing capacity expansion in Japan.

Therapies 40

Therapies Treatment Vaccine Production 40

PPD

OCTOBER 18, 2023

There has been an unprecedented expansion of different types of pharmaceutical therapies, as well as a change in the overall approach to health care. Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030.

Laboratories 52

Laboratories Assay Development Small Molecule Packaging 52

Drug Discovery World

JANUARY 2, 2024

She believes we might start to see a combination of vaccines with other immunotherapies or classical therapies out there, and that this will become more and more prevalent because of the nature of cancer. He said: “Between now and 2030, we’re going to see a range of vaccines using various technologies.

Research 148

Research Vaccine Science Trials 148

Drug Target Review

SEPTEMBER 22, 2023

Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. billion by 2030. Organoids for cell therapy and drug discovery. Cell Stem Cell [Internet]. 2023 May;30(5):571–91. Elsevier; 2020.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

DrugBank

MARCH 7, 2024

adults using obesity medications by 2030, further underlining the growing significance of this sector. Combination Therapies : Recognizing the complex nature of obesity, pharmaceutical companies are investigating combination therapies that target multiple pathways involved in appetite regulation, energy expenditure, and metabolic homeostasis.

Pharmaceutical Companies 81

Pharmaceutical Companies Pharmaceuticals Clinical Trials Pharmacokinetics 81

The Pharma Data

OCTOBER 9, 2021

Alzheimer’s is the most common form of madness, which presently affects farther than 55 million people worldwide, and is projected to reach 78 million by 2030. trillion per space by 2030. Much 10 million people widely are diagnosed with Notice each space.

Disease 52

Disease FDA Therapies Testimonials 52

Drug Discovery World

OCTOBER 6, 2022

until 2030. Scientific and technological breakthroughs are on the horizon in areas such as targeted protein degradation, cell antigene therapies to customise drugs and monoclonal antibodies being modified in new ways.” . Lu Rahman highlights some of the key players. . The European drug discovery sector is buoyant. Valued at $14.8

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Pharma Companies Marketing 130

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. recent announcements from Merck and Sanofi for obesity and broader metabolic disease).

Small Molecule 140

Small Molecule Trials Therapies Disease 140

DrugBank

MARCH 15, 2024

billion in 2022 and is projected to grow at a compound annual growth rate of 9.94% from 2023 to 2030. billion, Mounjaro's performance is a testament to the booming demand for innovative therapies targeting diabetes and obesity.  With sales soaring to $2.2

Pharmaceutical Companies 69

Pharmaceutical Companies Pharmaceuticals Treatment Marketing 69

Vial

MAY 20, 2024

billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. The role of this type of CRO is pivotal in the drug development process to determine whether a new therapy is well-tolerated in the general population over a longer period of time. What is a Pre-Clinical CRO? over this period.

Clinical Research 52

Clinical Research Research Clinical Trials Laboratories 52

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. It is approved in the U.S.

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52

The Pharma Data

MAY 26, 2023

With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. We will showcase significant steps toward that goal with overall survival data from ADAURA that reinforce Tagrisso as the backbone therapy in EGFR-mutated lung cancer.”

Therapies 40

Therapies Trials Treatment Disease 40

Drug Target Review

DECEMBER 4, 2023

What’s more, investment in this sector is predicted to rise by 70 percent by 2030. 4 The potential impact on patient outcomes that this will enable is colossal, but further advancement must be made to make such therapies truly accessible. The reason for all this attention and investment is clear: significant benefits for patients.

Treatment 105

Treatment Science DNA Doctors 105

Drug Discovery World

DECEMBER 12, 2022

Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening to read in the Guardian 1 that the NHS in the UK believes that by 2030 there will be no new cases of HIV in England. Everyone enjoys a good news story and the drug discovery and development sector is no exception.

Drugs 130

Drugs Engineering Clinical Trials Science 130

Drug Discovery World

FEBRUARY 10, 2023

This is reflected in the government’s aim of becoming a leader in the ATMP space by 2030. For instance, Swedish biotech Lokon Pharma worked with the Testa Center for nine weeks on a project to scale up its manufacturing process for its gene therapy candidate. Having our process verified at Testa Center is pure risk minimisation.

Science 130

Science Drugs Pharmaceutical Companies Pharmaceuticals 130

Drug Discovery World

APRIL 25, 2023

Amplify Therapeutics boasts disease-modifying therapies for Gaucher disease and genetic subgroups of Parkinson’s disease. billion by 2030. METSYSTEM offers a technology designed to predict cancer metastasis and determine the optimal chemotherapy to treat it preventively. Anti-ageing science therefore has huge value.

Science 130

Science Small Molecule Disease Government 130

The Pharma Data

MARCH 2, 2021

The companies share the goal of providing new obesity therapies with increased tolerability that support greater weight loss than current therapy options. We are committed to becoming a leader in the obesity space and to providing new therapy options to help people with high unmet medical needs.”. population will have obesity.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

NOVEMBER 1, 2021

At Boehringer Ingelheim, making our planet healthier is an integral part of our purpose to pioneer breakthrough therapies that transform the lives of humans and animals for generations. Boehringer Ingelheim Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals.

International 52

International Pharmaceuticals Therapies Pharmaceutical Companies 52

The Pharma Data

JULY 15, 2021

The collaboration will introduce a more virtual approach to the evaluation of Alzheimer’s prevention therapies. The current annual societal and economic cost of dementia is estimated at $1 trillion, an amount that is expected to double by 2030 unless we find a way to slow the disease 2.

Trials 52

Trials Clinical Trials Therapies Disease 52